Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in the Treatment of Intermediate to High Risk Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs Apalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms NEAR
- 27 Nov 2019 Status changed from active, no longer recruiting to completed.
- 07 Apr 2019 Planned End Date changed from 30 Aug 2018 to 30 Jun 2019.
- 07 Apr 2019 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.